粒径
生物利用度
材料科学
药品
结晶
粒度分布
粒子(生态学)
剂型
关键质量属性
溶解度
工艺工程
色谱法
纳米技术
化学工程
药理学
化学
医学
工程类
有机化学
地质学
海洋学
作者
Jon Hilden,Christopher L. Burcham,Stephen D. Stamatis,Jim Miesle,Carrie A. Coutant
出处
期刊:AAPS advances in the pharmaceutical sciences series
日期:2018-01-01
卷期号:: 277-302
被引量:2
标识
DOI:10.1007/978-3-319-94174-5_7
摘要
Drug substance particle size is a critical propertyOral dosage forms affecting drug product performance. Smaller particles dissolve faster and may improve bioavailability of the drug as a result. Smaller particles are typically dispersed more uniformly, leading to lower inter-tablet potency variation. Unfortunately, smaller particles can also result in poor powder handling characteristics or other processing issues. For example, powders can fail to flow through hoppers or stick to tooling surfaces, leading to poor tablet weight uniformity or tablet appearance issues. During crystallization, smaller particles can also be difficult to filter from the crystallization media. This can lead to higher levels of residual solvents and other impurities. Particle design and size selection are therefore critical to achieving a balance between manufacturability, bioavailability, and content uniformityContent uniformity . In this chapter, the impact of particle size on bioavailability is introduced and the impact on content uniformityUniformity dosage units is considered in depth. Control of the variability of tablet potency is discussed in relation to the overall particle size distribution. The risk-based selection of a positive control such as a screen to limit the maximum allowable particle size is discussed in relation to the occurrence of rare, but highly super-potent tablets.
科研通智能强力驱动
Strongly Powered by AbleSci AI